Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2023-04-18 00:00:00 ET · period of report 2023-04-17 · accession 0001209191-23-024724 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-18 | 2023-04-17 | VKTX | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $20.45 | -155.0K | 2.28M | -6% | -$3.17M |
| D | 2023-04-18 | 2023-04-17 | VKTX | Lian Brian | Pres, CEO, Dir | M - OptEx | $2.15 | +125.0K | 2.43M | +5% | +$268.8K |
| D | 2023-04-18 | 2023-04-17 | VKTX | Lian Brian | Pres, CEO, Dir | M - OptEx | $0.00 | -125.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2023-04-17 | S | D | 155,000 | $20.45 | 2,277,963 | D | — | — | |
| 2 | Common | Common Stock, par value $0.00001 per share | 2023-04-17 | M | A | 125,000 | $2.15 | 2,432,963 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-04-17 | M | D | 125,000 | $0.00 | 0 | D | $2.15 · 2017-03-04 to 2026-03-04 | 125,000 Common Stock | (F2) 25% of the shares subject to the option vested on each anniversary of the grant date. |